MBX insider trading
HealthcareMBX Biosciences, Inc.: insider trade history from SEC Form 4 filings.
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Company website: mbxbio.com
MBX insider activity at a glance
FilingIQ tracks 78 insider transactions for MBX in filings since Sep 17, 2024. The most recent transaction is dated Aug 4, 2026.
Across the full history, 31 open-market purchases
and 5 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MBX insider trades is 55.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MBX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MBX?
- FilingIQ tracks 78 Form 4 insider transactions for MBX (MBX Biosciences, Inc.), covering filings from Sep 17, 2024 onwards. 3 of those are dated within the last 90 days.
- Are MBX insiders net buyers or net sellers?
- Across the full Form 4 history for MBX, 31 transactions (40%) were open-market purchases and 5 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MBX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is MBX in?
- MBX Biosciences, Inc. (MBX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.75B.
Methodology & sources
Every MBX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.